Xyphos Biosciences
Xyphos Biosciences is a pre-commercial biotech subsidiary of Astellas Pharma developing a proprietary convertibleCAR™ cell therapy platform that modifies the NKG2D receptor to enable controllable immune cell targeting of solid-tumor and hematological cancer antigens.
- Company typePrivate
- Founded2017
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Xyphos Biosciences does
Xyphos Biosciences is a clinical-stage biotechnology company developing a proprietary convertibleCAR™ cell therapy platform for treating cancer, with a stated focus on relapsed hematological malignancies and solid tumors. The company's core technology modifies the natural NKG2D receptor on immune cells — including natural killer cells and T-cells — to enable controllable targeting of tumor antigens via engineered bispecific antibodies. Its complementary ACCEL™ (Advanced Cellular Control through Engineered Ligands) platform allows functional molecules such as bispecific antibodies to be attached to immune cells, providing the ability to engineer and re-engineer therapies inside the body to address tumor antigens that change to evade detection. Headquartered in South San Francisco, California, Xyphos holds registered trademarks for both the convertibleCAR™ and ACCEL™ brands and operates an R&D site led by a PhD-level management team with experience across Merck Research Labs, Pfizer, Novartis, Adicet Bio, and Agensys/Astellas.
Xyphos operates as a wholly owned subsidiary of Astellas Pharma (TYO: 4503) and functions as Astellas' Cancer Cell Therapy division. Its commercial model is not product sales but research collaboration and licensing. The most significant commercial event is the May 2024 research collaboration and license agreement with Poseida Therapeutics, under which Poseida receives a $50 million upfront payment, up to $550 million in development and sales milestones, and low double-digit tiered royalties on net sales, in exchange for combining Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology to develop convertibleCAR programs targeting solid-tumor cancers. Concurrently, Astellas invested $50 million in Poseida ($25 million for shares and $25 million for exclusive negotiation rights on Poseida's P-MUC1C-ALLO1 program), securing a board observer seat. Beyond the Poseida arrangement, Xyphos generates no disclosed product revenue; pricing is not publicly disclosed as the company is pre-commercial.
The company is pre-commercial and currently pre-revenue, with go-to-market executed via enterprise licensing and OEM-style partnerships rather than traditional biopharma distribution. Its customer base consists of biopharmaceutical partners (Poseida being the single named external counterparty) plus its parent Astellas, which provides internal R&D funding. Marketing is limited to a corporate website, LinkedIn presence via Astellas, and educational video content. Founded in 2017, Xyphos is a privately held Delaware/California corporation with a small core employee base (1-10 per firmographic data) supplemented by senior directors and a dedicated leadership team.
Xyphos Biosciences firmographics
Firmographics- Name
- Xyphos Biosciences
- Legal name
- Xyphos Biosciences, Inc.
- Website
- https://xyphosinc.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Xyphos Biosciences is a pre-commercial biotech subsidiary of Astellas Pharma developing a proprietary convertibleCAR™ cell therapy platform that modifies the NKG2D receptor to enable controllable immune cell targeting of solid-tumor and hematological cancer antigens.
- Ownership category
- akta.pro rank
Xyphos Biosciences industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industries
- NK Cell Therapies (HLAAABAD), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where Xyphos Biosciences is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Xyphos Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Research Collaboration and Licensing: Xyphos generates revenue through research collaborations and licensing agreements with pharmaceutical partners. Under the Poseida partnership, the company receives upfront payments ($50M), potential development and sales milestones (up to $550M), and tiered royalties on net sales (low double-digit percentages).
- Technology Investment Returns: As a subsidiary of Astellas Pharma, revenue is generated through internal technology transfer and development funding from the parent company, supporting advancement of the cancer cell therapy platform through clinical development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Xyphos Biosciences product offering
Product offeringCore offering
Xyphos Biosciences develops a flexible and controllable immune cell therapy platform for cancer treatment using its proprietary convertibleCAR™ and ACCEL™ technologies. The platform modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells through engineered bispecific antibodies that can be adapted to recognize single or multiple tumor antigens. The technology is offered through research collaborations and licensing agreements with pharmaceutical partners for co-development and commercialization of cell therapy programs.
Product overview
Xyphos Biosciences is developing a flexible and controllable immune cell therapy platform for cancer treatment. Their core technology is the convertibleCAR™ platform, which utilizes ACCEL™ (Advanced Cellular Control through Engineered Ligands) technology to create cell therapies that can be engineered and re-engineered inside the body to target single or multiple tumor antigens. The platform modifies the NKG2D receptor on immune cells and uses engineered molecules (bispecific antibodies) to enable specific tumor targeting while avoiding immune rejection. Xyphos operates as a wholly owned subsidiary of Astellas Pharma, serving as Astellas' Cancer Cell Therapy center.
Differentiator
Problem solved
Functional benefit
Brands
- convertibleCAR: Proprietary convertibleCAR (Chimeric Antigen Receptor) technology that creates flexible cell therapies engineered to target multiple tumor antigens by utilizing a modified NKG2D receptor.
- ACCEL Technology
Products and services
- convertibleCAR™ Platform Proprietary chimeric antigen receptor (CAR) platform that modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells. The platform uses engineered bispecific antibodies to redirect immune cell specificity, allowing the therapy to be engineered and re-engineered inside the body to target single or multiple tumor antigens and adapt as tumors evolve to evade detection. Offered to biopharmaceutical partners for co-development and commercialization of cell therapy programs.
- ACCEL™ (Advanced Cellular Control through Engineered Ligands) Technology Technology platform enabling attachment of various functional molecules, including bispecific antibodies, to engineered immune cells to redirect their targeting. ACCEL provides greater speed and flexibility than currently approved CAR-T therapies and supports off-the-shelf, Standard Pharmaceutical-like Cell Therapy applications for solid-tumor and hematological cancer programs.
- Research Collaboration and Licensing of convertibleCAR Programs B2B research collaboration and licensing offering in which Xyphos grants biopharmaceutical partners access to its convertibleCAR and ACCEL technologies for the co-development and commercialization of cell therapy programs, with revenue from upfront payments, development and sales milestones, and tiered royalties on net sales.
Quantifiable outcome
- Potential to target multiple tumor antigens with a single therapy platform
Companies that use Xyphos Biosciences
Customer profileSegments1 record
Ideal customer profiles2 records
Xyphos Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Xyphos Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Poseida TherapeuticscoreAstellas Pharma's wholly owned subsidiary Xyphos Biosciences entered into a research collaboration and license agreement with Poseida Therapeutics to develop convertibleCAR programs targeting solid-tumor cancers. The collaboration combines Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology. Poseida receives $50 million upfront payment plus potential development and sales milestones and contingency payments totaling up to $550 million, as well as low double-digit tiered royalties on net sales. Additionally, Astellas is investing $50 million total in Poseida, comprising $25 million to acquire shares and a $25 million payment for exclusive negotiation rights on Poseida's clinical-stage P-MUC1C-ALLO1 program, with Astellas gaining a board observer seat.
Scale indicators3 records
Recent moves1 record
Expansion highlights5 records
Xyphos Biosciences competitors and assessment
Company assessmentEmerging players
- Cellectis: Clinical-stage allogeneic CAR-T developer using TALEN gene editing. Comparable to Xyphos in targeting solid tumors with engineered allogeneic platforms, though at earlier commercial stage.
Direct peers
- Adicet Bio: Develops gamma delta T cell therapies for cancer with off-the-shelf, allogeneic platform. Leadership includes Xyphos' Daulet Satpayev (formerly VP Research at Adicet). Directly comparable in adaptive immune cell therapy for solid tumors.
- Century Therapeutics: iPSC-derived allogeneic cell therapy platform for oncology. Comparable to Xyphos in pursuing engineered, off-the-shelf immune cell approaches with potential for multiplexed targeting.
- Fate Therapeutics: Develops iPSC-derived NK cell and T-cell therapies for cancer, with an off-the-shelf, multiplexed platform directly comparable to Xyphos' NK cell-based convertibleCAR approach. Both target solid tumors and hematologic malignancies with engineered immune cells.
- Caribou Biosciences: Allogeneic CAR-T and CAR-NK developer using CRISPR gene editing for next-gen cell therapies. Directly comparable to Xyphos in applying engineered immune cell approaches to overcome tumor resistance.
- Poseida Therapeutics: Allogeneic CAR-T platform developer and Xyphos' primary collaboration partner. Poseida's P-MUC1C-ALLO1 program combines with Xyphos' ACCEL technology, making it the most directly comparable peer in next-gen cell therapy for solid tumors.
- Nkarta Therapeutics: Pure-play NK cell therapy developer using engineered CAR-NK platforms for solid tumors and hematologic malignancies. Highly comparable to Xyphos' NK cell-based convertibleCAR platform in modality, target indications, and adaptive targeting strategies.
- Allogene Therapeutics: Leading allogeneic CAR-T developer with multiple clinical-stage programs. Comparable to Xyphos as a next-generation off-the-shelf cell therapy platform targeting both hematologic malignancies and solid tumors.
Broad incumbents
- CRISPR Therapeutics: Gene-edited cell therapy leader with approved Casgevy and a broad pipeline. Comparable to Xyphos in next-gen cell therapy platforms but operates at a much larger scale with diversified technology assets.
- Gilead Sciences (Kite Pharma): Commercial CAR-T leader via Kite (Yescarta, Tecartus) and broader immuno-oncology portfolio. Sets the competitive standard for cell therapy commercialization against which Xyphos' next-gen platform must compete.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Xyphos Biosciences social profiles
Digital presenceXyphos Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xyphos Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
Xyphos Biosciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xyphos Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xyphos Biosciences
What does Xyphos Biosciences do?
Xyphos Biosciences develops a flexible and controllable immune cell therapy platform for cancer treatment using its proprietary convertibleCAR™ and ACCEL™ technologies. The platform modifies the natural NKG2D receptor on natural killer cells and T-cells to enable controllable targeting of tumor cells through engineered bispecific antibodies that can be adapted to recognize single or multiple tumor antigens. The technology is offered through research collaborations and licensing agreements with pharmaceutical partners for co-development and commercialization of cell therapy programs.
Is Xyphos Biosciences a public or private company?
Xyphos Biosciences is a private company. It is classified as corporate owned and is currently operating.
When was Xyphos Biosciences founded?
Xyphos Biosciences was founded in 2017. It employs 1 to 10 people.
Where is Xyphos Biosciences based?
Xyphos Biosciences is headquartered in San Francisco, United States, in the North America region.
How does Xyphos Biosciences make money?
Two revenue lines are on record. Research Collaboration and Licensing is the primary driver. The others are technology Investment Returns.
Who are Xyphos Biosciences's main competitors?
Cellectis is listed as an emerging player. Direct peers are Adicet Bio, Century Therapeutics, Fate Therapeutics, Caribou Biosciences, Poseida Therapeutics, Nkarta Therapeutics and Allogene Therapeutics. Broad incumbents are CRISPR Therapeutics and Gilead Sciences (Kite Pharma).
Does Xyphos Biosciences have an API?
No public API is recorded for Xyphos Biosciences.
What industry is Xyphos Biosciences in?
Xyphos Biosciences's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAD, NK Cell Therapies. Its NAICS code is 325414 and its SIC code is 2834.